Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:25 AM
Ignite Modification Date:
2025-12-25 @ 1:25 AM
NCT ID:
NCT04929093
Eligibility Criteria:
Inclusion Criteria:
* (1) aged 18 to 60 years;
* (2) only had a positive response to Der p and Der f but no other inhalant allergens based on EUROline Allergy Diagnostics (Beijing Oumeng Biotechnology Co., Ltd., Beijing, China). Meanwhile at least Der p -specific IgE (sIgE) in serum of was ≥ 0.7 kU/l (CAP Pharmacia, Uppsala, Sweden) using ImmunoCAP system (Pharmacia, Uppsala, Sweden) regardless of the result of Der p -specific IgE in serum;
* (3) had reached cluster SCIT maintenance period and the overall treatment time was more than 1 year but less than 2 years;
* (4) hope to continue to complete the entire treatment and have good compliance.
Exclusion Criteria:
* (1) diagnosed as asthma based on the guidelines of the Global Initiative for Asthma(13);
* (2) had Grade II or above systemic adverse reactions occurred in the past SCIT period.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
5 Years
Maximum Age:
53 Years
Study:
NCT04929093
Study Brief:
Protocol Section:
NCT04929093